A compound in green tea may offer a potential new approach to combating the joint pain, inflammation and tissue damage caused by rheumatoid arthritis.
A compound in green tea may offer a potential new approach to combating the joint pain, inflammation and tissue damage caused by rheumatoid arthritis.
As India's pharmaceutical companies continue to look for greener pastures for growth, the 70 participants in the two-day IPHEX Africa trade exhibition in the Nigerian commercial capital of Lagos will be aiming to increase their exports to western Africa where they see a significant growth potential.
Oral bacteria may be involved in several kinds of stroke, including brain hemorrhages and strokes that lead to dementia, says a new study.
Don't let the high blood pressure that you have been diagnosed with scare you out of your wits. It is not exactly a disease, but only a warning sign that the food you have been eating and the lifestyle you have been leading have clogged your blood vessels and your heart is having to exert extra pressure to keep blood moving through it.
Paving the way for new depression treatments, researchers have discovered the first-ever connection between vulnerability to depression and a type of brain cells called noradrenergic neurons.
45-year-old patient suffering from Parkinson's disease showed sharp improvement after undergoing stem cell therapy, according to claims made by the doctor who treated him.
A new class of antigens has been identified that may be a contributing factor to type 1 diabetes. Type-1 diabetes is the auto-immune form of diabetes, in which insulin-producing beta cells in the pancreas are destroyed by body's own immune cells, a study finds.
Enriching T cells a type of white blood cell to attack certain cancerous diseases may prove beneficial to an increasing number of children during immunotherapy, says a study.
Long-term use of liraglutide, a drug used to lower blood sugar levels in type 2 diabetes patients, can have a deteriorating effect on insulin-producing cells, leading to an increase in blood sugar levels, warns a study.
KemPharm, Inc. announced that the New Drug Application (NDA) for KP201/APAP, its investigational drug candidate for the short-term management of acute pain, has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA). In addition, the FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 9, 2016.